OMER On Other Exchanges
text size: T | T
Back to Snapshot
Company Description

Contact Info

201 Elliott Avenue West

Seattle, WA 98119

United States

Phone: 206-676-5000

Fax: 206-676-5005

ies targeting MASP-2 and the therapeutic applications for those antibodies from the University of Leicester, from its collaborator, Medical Research Council at Oxford University (MRC), and from Helion Biotech ApS, or Helion. Phosphodiesterase 10 (PDE10) Programs - OMS824 for Huntington’s Disease and Schizophrenia OMS824 is in a Phase 2 clinical program for the treatment of Huntington’s disease and a Phase 2 clinical program evaluating OMS824 for the treatment of schizophrenia. The company is preparing for a re-designed Phase 2 clinical trial in patients with Huntington’s disease. In its schizophrenia program, the company completed a Phase 2a trial evaluating OMS824’s tolerability, safety, pharmacokinetics, potential interactions with concomitant antipsychotic medications, and potential effects on cognition using a battery of cognitive tests in patients with schizophrenia. Peroxisome Proliferator-Activated Receptor Gamma (PPAR?) Program - OMS405 In its PPAR?, program, the company is developing proprietary compositions that include PPAR? agonists for the treatment and prevention of addiction to substances of abuse, which may include opioids, nicotine and alcohol. The company’s collaborators at The New York State Psychiatric Institute have completed two Phase 2 clinical trials related to its PPAR? program. OMS201-Urology OMS201 is the company’s PharmacoSurgery product candidate designed for use during urological procedures, including ureterscopy for removal of ureteral or renal stones. OMS201 is a proprietary combination of ketoprofen, an anti-inflammatory active pharmaceutical ingredient (API), and nifedipine, a muscle relaxant API. Preclinical Programs Phosphodiesterase 7 (PDE7) Program - OMS527 The company’s PDE7 program is based on the company’s discoveries of previously unknown links between PDE7 and any addiction or compulsive disorder and between PDE7 and any movement disorders, such as Parkinson’s disease. PDE7 appears to modulate the dopaminergic system, which plays a significant role in regulating both addiction and movement. The company holds an exclusive license to certain PDE7 inhibitors claimed in patents and pending patent applications owned by Daiichi Sankyo Co., Ltd. (Daiichi Sankyo), for use in the treatment of movement, addiction and compulsive disorders, as well as other specified indications. Plasmin Program - OMS616 In its plasmin program, the company is advancing novel antifibrinolytic agents for the control of blood loss during surgery or resulting from trauma as well as for other hyperfibrinolytic states (liver disease). The company holds a worldwide exclusive license to patent rights related to certain antifibrinolytics from The Regents of the University of California. Mannan-Binding Lectin-Associated Serine Protease-3 (MASP-3) Program - OMS906 - Alternative Pathway Disorders The company is developing MASP-3 inhibitors for the treatment of disorders related to the alternative pathway of the complement system and is optimizing potent and functionally active antibodies in preparation for scale-up of one or more clinical candidates. The company jointly owns and holds worldwide exclusive license rights related to therapeutic applications for inhibiting MASP-3 from the University of Leicester. GPCR Platform The company developed a proprietary cellular redistribution assay (CRA), which it uses in a high-throughput manner to identify synthetic ligands, including antagonists, agonists and inverse agonists that bind to and affect the function of orphan GPCRs. GPR17 Program The company is conducting medicinal chemistry to optimize compounds against GPR17, a GPCR that is linked to myelin formation. GPR101 Program The company is conducting medicinal chemistry to optimize compounds against GPR101, a GPCR that is linked to appetite and eating disorders. GPR151 Program The company is conducting medicinal chemistry to optimize compounds against GPR151, a GPCR that is linked to neuropathic pain and cognitive disorders. GPR161 Program The company is conducting medicinal chemistry to optimize compounds against GPR161, a GPCR that is linked to t


The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

OMER Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for OMER.
View Industry Companies

Industry Analysis


Industry Average

Valuation OMER Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 11.5x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 9.2x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact OMEROS CORP, please visit Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at